KUWAIT DRUGS

 

SEARCH

 

SUGGESTIONS

 

ADD PRODUCTS

 

HOME

0-9    A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

 

 

PREVIOUS

  

NEXT

 
 

RANTAG 50 MG/2 ML INJECTION

 

 
 

 

GENERIC NAMES

MANUFACTURERS 

MEDICAL GROUP

MEDICAL ARTICLES

 

DRUGS IN :

 

 

FDA DRUGS

UNITED STATES

CANADA

UNITED KINGDOM

AUSTRALIA

GERMANY

FRANCE

MIDDLE EAST

KUWAIT

LEBANON

EGYPT

SYRIA

BAHRAIN

IRAN

JORDAN

SAUDI ARABIA

UNITED ARAB EMIRATES

 

 

 
 

SIZE:

50 MG/2 ML

 

GENERIC NAME:

RANITIDINE

 

MANUFACTURER:

JULPHAR

 

UNIT:

 

ADMINISTRATION ROUTE:

 

FDA PREGNANCY GROUP:

B

 

INDICATIONS:

Esophagitis, erosive

Gastroesophageal Reflux Disease

Mastocytosis, systemic

Ulcer, duodenal

Ulcer, gastric

Zollinger- Ellison syndrome

 

SIDE EFFECTS:

abdominal pain

agitation

agranulocytosis

alopecia

anaphylactoid reactions

angioedema

aplastic anemia

arthralgia

AV block

blurred vision

bronchospasm

confusion

constipation

delirium

depression

diarrhea

dizziness

elevated hepatic enzymes

eosinophilia

erythema multiforme

gynecomastia

hallucinations

headache

hemolytic anemia

hepatitis

impotence

insomnia

jaundice

leukopenia

libido decrease

maculopapular rash

myalgia

nausea/vomiting

neutropenia

pancreatitis

pancytopenia

paranoia

premature ventricular contractions (PVCs)

sinus bradycardia

sinus tachycardia

Stevens-Johnson syndrome

thrombocytopenia

toxic epidermal necrolysis

vasculitis

 

ABSOLUTE CONTRAINDICATIONS :

 

RELATIVE CONTRAINDICATIONS :

breast-feeding

children

elderly

gastric cancer

2-blocker*hypersensitivity#243"H2-blocker hypersensitivity

infants

infection

neonatal prematurity

neonates

phenylketonuria

porphyria

pregnancy

renal disease

renal failure

renal impairment

 

ADULT DOSE:

Duodenal ulcer or Gastric ulcer or Gastric hypersecretory conditions (e.g., Zollinger-Ellison syndrome, systemic mastocytosis, multiple endocrine adenomas) and [Prophylaxis of stress-related mucosal bleeding]-Intramuscular, 50 mg every six to eight hours. Intravenous, 50 mg every six to eight hours, diluted to a total volume of 20 mL with a compatible intravenous solution and administered over a period of not less than five minutes. Intravenous infusion, 50 mg every six to eight hours, diluted in 100 mL of a compatible intravenous solution and administered over a fifteen- to twenty-minute period. Continuous intravenous infusion, 6.25 mg per hour, diluted in a compatible intravenous solution. Note: For gastric hypersecretory conditions, the infusion should be started at 1 mg per kg of body weight per hour and increased by 0.5 mg per kg of body weight per hour increments (if gastric acid output is greater than 10 mEq per hour or patient is symptomatic), up to 2.5 mg per kg of body weight per hour. [Prophylaxis of aspiration pneumonitis]-Intramuscular or slow intravenous injection, 50 mg administered forty-five to sixty minutes before induction of general anesthesia. Note: For patients with impaired renal function (creatinine clearance of less than 50 mL per minute)-Intravenous, 50 mg every eighteen to twenty-four hours, the frequency of the dosage being increased to every twelve hours or more frequently, if necessary. Further reduction in dosage may be required if hepatic function impairment is also present.

 

MAXIMUM ADULT DOSE:

400 mg a day.

 

PEDIATRIC DOSE:

Duodenal ulcer or Gastric ulcer-Intravenous infusion, 2 to 4 mg per kilogram of body weight a day , diluted to a suitable volume with a compatible intravenous solution and administered over a fifteen- to twenty-minute period Gastroesophageal reflux-Intravenous infusion, 2 to 8 mg per kg of body weight, diluted in a suitable volume with a compatible intravenous solution and administered over a fifteen- to twenty-minute period, three times a day. Note: In certain circumstances, doses may be titrated based on gastric pH. 

 

MAXIMUM PEDIATRIC DOSE:

 

ELDERLY DOSE:

Duodenal ulcer or Gastric ulcer or Gastric hypersecretory conditions (e.g., Zollinger-Ellison syndrome, systemic mastocytosis, multiple endocrine adenomas) and [Prophylaxis of stress-related mucosal bleeding]-Intramuscular, 50 mg every six to eight hours. Intravenous, 50 mg every six to eight hours, diluted to a total volume of 20 mL with a compatible intravenous solution and administered over a period of not less than five minutes. Intravenous infusion, 50 mg every six to eight hours, diluted in 100 mL of a compatible intravenous solution and administered over a fifteen- to twenty-minute period. Continuous intravenous infusion, 6.25 mg per hour, diluted in a compatible intravenous solution. Note: For gastric hypersecretory conditions, the infusion should be started at 1 mg per kg of body weight per hour and increased by 0.5 mg per kg of body weight per hour increments (if gastric acid output is greater than 10 mEq per hour or patient is symptomatic), up to 2.5 mg per kg of body weight per hour. [Prophylaxis of aspiration pneumonitis]-Intramuscular or slow intravenous injection, 50 mg administered forty-five to sixty minutes before induction of general anesthesia. Note: For patients with impaired renal function (creatinine clearance of less than 50 mL per minute)-Intravenous, 50 mg every eighteen to twenty-four hours, the frequency of the dosage being increased to every twelve hours or more frequently, if necessary. Further reduction in dosage may be required if hepatic function impairment is also present.

 

 

PREVIOUS

  

NEXT